Clincosm LogoSign in Get a demo

apatinib

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)

Not yet recruiting
  • Melanoma
  • +6 more
  • (no location specified)
Aug 21, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Chemotherapy plus apatinib)

Completed
  • Recurrent Cervical Carcinoma
  • +5 more
  • Chemotherapy plus apatinib
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Apatinib Trial in Shanghai (Apatinib, Oxaliplatin, 5-fluorouracil)

Enrolling by invitation
  • Apatinib
  • Shanghai, China
    Huashan Hospital Affiliated to Fudan University
Sep 19, 2021

Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib Trial in Chengdu (DEB-TACE combined with apatinib and

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • +3 more
  • DEB-TACE combined with apatinib and PD-1 antibody
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital and Research Institute
Apr 4, 2021

Neoadjuvant Therapy, Carilizumab, Apatinib Trial in Guangzhou (PD-1)

Recruiting
  • Neoadjuvant Therapy
  • +3 more
  • PD-1
  • Guangzhou, Guangdong, China
    Cancer center of Sun Yat sen University
Oct 9, 2020

Hepato-Biliary Tumor, Pancreatic Cancer, Radiotherapy Trial (radiation, combination product, drug)

Not yet recruiting
  • Hepato-Biliary Neoplasm
  • +4 more
  • Radiotherapy
  • +3 more
  • (no location specified)
Sep 7, 2020

Esophageal Squamous Cell Carcinoma, Apatinib, Recurrence Trial in Shanghai (apatinib)

Unknown status
  • Esophageal Squamous Cell Carcinoma
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Feb 3, 2020

Apatinib, Outcome, Fatal, Colorectal Cancer Trial in Nanchong (Apatinib, CAPEOX)

Withdrawn
  • Apatinib
  • +4 more
  • Nanchong, Sichuan, China
    Yunhong Tian
Jan 31, 2020

Thyroid, Metastasis, Apatinib Trial in Nanjing (Apatinib)

Unknown status
  • Thyroid
  • +2 more
  • Nanjing, Jingsu, China
    Nanjing First Hospital
Nov 26, 2019

NSCLC, Apatinib, EGFR-TKI Trial in Shenzhen (Apatinib(Tab. 500mg/d) combined with EGFR-TKI(as previously))

Unknown status
  • NSCLC
  • +2 more
  • Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）
  • Shenzhen, Guangdong, China
    Shenzhen People's Hospital
Apr 2, 2019

Stomach Tumors, Gastrointestinal Tumors, Stomach Diseases Trial (Apatinib, Capecitabine)

Not yet recruiting
  • Stomach Neoplasms
  • +7 more
  • (no location specified)
Mar 23, 2019

Hepatocellular Carcinoma, Radiotherapy, Apatinib Trial in Guangzhou (Radiotherapy, Apatinib, Radiotherapy+apatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • Radiotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Nov 4, 2018

Lung Cancer, Non Small Cell Lung Cancer, Combination Chemo Trial in Chengdu (Apatinib, AP or AC, Apatinib 250mg)

Unknown status
  • Lung Cancer
  • +3 more
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Nov 16, 2017

Gastric Cancer, Apatinib, Biomarker Trial in Bengbu (Apatinib mesylate tablets)

Unknown status
  • Gastric Cancer
  • +2 more
  • Apatinib mesylate tablets
  • Bengbu, Anhui, China
    Department of Medical Oncology, First Affiliated Hospital of Ben
Sep 7, 2017

Malignant Ascites, Apatinib Trial in Bengbu (Apatinib)

Unknown status
  • Malignant Ascites
  • Apatinib
  • Bengbu, Anhui, China
    Qiong Wu
May 30, 2017

Esophageal Cancer, Metastatic Esophageal Cancer, Apatinib Trial in Hangzhou (Apatinib)

Unknown status
  • Esophageal Cancer
  • +2 more
  • Hangzhou, Zhejiang, China
    Hangzhou Cancer Hospital
Aug 25, 2016